Treatment related adverse event - trAE

Characteristics of second primary malignancies following bispecific antibodies therapy
Xiaojie Liang, Baiwei Luo, Bingyu Lin, Dan Liu, Jia Guo, Weixiang Lu, Shengyu Tian, Zihong Cai, Xinyu Zhou, Zhihao Jin, Tong Li, Keren Chen, Hongsheng Zhou, Liang Wang

Journal for ImmunoTherapy of Cancer Apr 2025, 13 (4) e011200; DOI: 10.1136/jitc-2024-011200
EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
Jan H Frenking, Xiang Zhou, Vivien Wagner, Thomas Hielscher, Joseph Kauer, Elias K Mai, Mirco J Friedrich, Christian S Michel, Marina Hajiyianni, Iris Breitkreutz, Patrick Costello, Omar Nadeem, Niels Weinhold, Hartmut Goldschmidt, Anita Schmitt, Thomas Luft, Michael Schmitt, Carsten Müller-Tidow, Max Topp, Hermann Einsele, Peter Dreger, Nikhil C Munshi, Adam S Sperling, Leo Rasche, Sandra Sauer, Marc S Raab

Journal for ImmunoTherapy of Cancer Oct 2024, 12 (10) e009220; DOI: 10.1136/jitc-2024-009220
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, Benjamin Neuditschko, Klaus Hackner, Judith Lind, Osman Aksoy, Uwe Graichen, Sascha Klee, Franz Herzog, Christoph Wiesner, Peter Errhalt, Martin Pecherstorfer, Klaus Podar, Sonia Vallet

Journal for ImmunoTherapy of Cancer May 2024, 12 (5) e008669; DOI: 10.1136/jitc-2023-008669
Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed et al
Yoshihiro Noguchi, Miao Yan, Tomoya Tachi, Tomoaki Yoshimura

Journal for ImmunoTherapy of Cancer Apr 2024, 12 (4) e009137; DOI: 10.1136/jitc-2024-009137

Log in using your username and password

Main menu

Log in using your username and password

You are here

Treatment related adverse event - trAE